Cover Image
市場調查報告書

BioInvent International AB:產品平台分析

BioInvent International AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 301289
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
BioInvent International AB:產品平台分析 BioInvent International AB - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 36 Pages
簡介

BioInvent International AB,是研究開發型製藥公司。專門以癌症治療抗體的藥物研發及開發為焦點。

本報告提供BioInvent International AB之調查分析,提供您治療藥的開發平台最新資訊,加上各開發階段比較分析,藥物標的·作用機制·給藥途徑·各分子類型的治療藥評估,也包含最新消息和新聞稿,後期階段·中止的計劃等系統性資訊。

目錄

BioInvent International AB的基本資料

  • BioInvent International AB概要
  • 主要資訊
  • 企業資料

BioInvent International AB:R&D概要

  • 主要的治療領域

BioInvent International AB:開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品:單獨療法
  • 開發中產品:合作夥伴產品
  • 開發中產品:轉出授權產品

BioInvent International AB:開發中產品的概要

  • 臨床階段的開發中產品
  • 初期階段的開發中產品

BioInvent International AB:藥物簡介

  • BI-505
  • BI-1206
  • Monoclonal Antibodies for Acute Myelocytic Leukemia
  • Monoclonal Antibodies for Blood Cancers
  • Monoclonal Antibodies for Chronic Lymphocytic Leukemia
  • Monoclonal Antibodies to Agonize 41BB for Cancer
  • Monoclonal Antibodies to Agonize OX40 for Cancer
  • Monoclonal Antibodies to Target Tumour-Associated Macrophages for Cancer
  • Monoclonal Antibody for Inflammation

BioInvent International AB:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

BioInvent International AB:開發平台的最新趨勢

BioInvent International AB:企業聲明

BioInvent International AB:所在地與子公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07118CDB

Summary

Global Markets Direct's, 'BioInvent International AB - Product Pipeline Review - 2015', provides an overview of the BioInvent International AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioInvent International AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BioInvent International AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BioInvent International AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BioInvent International AB's pipeline products

Reasons to buy

  • Evaluate BioInvent International AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BioInvent International AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BioInvent International AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BioInvent International AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioInvent International AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BioInvent International AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BioInvent International AB Snapshot
    • BioInvent International AB Overview
    • Key Information
    • Key Facts
  • BioInvent International AB - Research and Development Overview
    • Key Therapeutic Areas
  • BioInvent International AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • BioInvent International AB - Pipeline Products Glance
    • BioInvent International AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • BioInvent International AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • BioInvent International AB - Drug Profiles
    • BI-505
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BI-1206
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Acute Myelocytic Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Blood Cancers
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Chronic Lymphocytic Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize 41BB for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize OX40 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Tumour-Associated Macrophages for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BioInvent International AB - Pipeline Analysis
    • BioInvent International AB - Pipeline Products by Target
    • BioInvent International AB - Pipeline Products by Route of Administration
    • BioInvent International AB - Pipeline Products by Molecule Type
    • BioInvent International AB - Pipeline Products by Mechanism of Action
  • BioInvent International AB - Recent Pipeline Updates
  • BioInvent International AB - Company Statement
  • BioInvent International AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BioInvent International AB, Key Information
  • BioInvent International AB, Key Facts
  • BioInvent International AB - Pipeline by Indication, 2015
  • BioInvent International AB - Pipeline by Stage of Development, 2015
  • BioInvent International AB - Monotherapy Products in Pipeline, 2015
  • BioInvent International AB - Partnered Products in Pipeline, 2015
  • BioInvent International AB - Partnered Products/ Combination Treatment Modalities, 2015
  • BioInvent International AB - Out-Licensed Products in Pipeline, 2015
  • BioInvent International AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • BioInvent International AB - Phase II, 2015
  • BioInvent International AB - Preclinical, 2015
  • BioInvent International AB - Discovery, 2015
  • BioInvent International AB - Pipeline by Target, 2015
  • BioInvent International AB - Pipeline by Route of Administration, 2015
  • BioInvent International AB - Pipeline by Molecule Type, 2015
  • BioInvent International AB - Pipeline Products by Mechanism of Action, 2015
  • BioInvent International AB - Recent Pipeline Updates, 2015
  • BioInvent International AB, Subsidiaries

List of Figures

  • BioInvent International AB - Pipeline by Top 10 Indication, 2015
  • BioInvent International AB - Pipeline by Stage of Development, 2015
  • BioInvent International AB - Monotherapy Products in Pipeline, 2015
  • BioInvent International AB - Partnered Products in Pipeline, 2015
  • BioInvent International AB - Out-Licensed Products in Pipeline, 2015
  • BioInvent International AB - Pipeline by Top 10 Target, 2015
  • BioInvent International AB - Pipeline by Top 10 Molecule Type, 2015
  • BioInvent International AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top